{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:30:41Z","timestamp":1790566241053,"version":"4.1.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Although commonly used as the primary outcome measure of clinical trials in pulmonary arterial hypertension (PAH), the minimal important difference (MID) of the 6-minute walk test (6MWT) has not been well defined for this population of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To estimate the MID in the 6MWT in patients with PAH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Study subjects from the clinical trial of tadalafil in PAH, a 16-week, parallel-group, randomized clinical trial of patients who were treatment naive or on background therapy with an endothelin receptor antagonist, were eligible. 6MWT was performed using a standardized protocol. Distributional and anchor-based methods were used to estimate the MID; the latter method used the Physical Component Summary Score (PCS) of the Medical Outcomes Study 36-item short form (SF-36).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Four hundred five subjects were analyzed. Domains of the SF-36 were weakly to modestly associated with 6MWT. Change in the PCS of the SF-36 was most strongly associated with change in 6MWT (r = 0.40, P &amp;lt; 0.001) and thus was selected as the anchor for subsequent anchor-based analyses. Distributional analyses yielded estimates of the MID ranging from 25.1 to 38.5 m, whereas anchor-based analyses yielded an estimate of 38.6 m.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Using both distributional and anchor-based methods, the estimated consensus MID in the 6MWT for PAH is approximately 33 m. These results have important implications for (1) assessing treatment responses from clinical trials and metaanalyses of specific PAH therapy, and (2) sample size calculations for future study design.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201203-0480oc","type":"journal-article","created":{"date-parts":[[2012,6,22]],"date-time":"2012-06-22T12:14:07Z","timestamp":1340367247000},"page":"428-433","source":"Crossref","is-referenced-by-count":247,"title":["The Minimal Important Difference in the 6-Minute Walk Test for Patients with Pulmonary Arterial Hypertension"],"prefix":"10.1093","volume":"186","author":[{"given":"Stephen C.","family":"Mathai","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milo A.","family":"Puhan","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Lam","sequence":"additional","affiliation":[{"name":"United Therapeutics Corporation, Research Triangle Park, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Wise","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,9,1]]},"reference":[{"key":"2026032101021998600_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00019501-200502000-00003","article-title":"The right ventricle in pulmonary hypertension","volume":"16","author":"Chin","year":"2005","journal-title":"Coron Artery Dis"},{"key":"2026032101021998600_bib2","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jacc.2009.01.004","article-title":"ACCF\/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association","volume":"53","author":"McLaughlin","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026032101021998600_bib3","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.healun.2010.11.009","article-title":"Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension","volume":"30","author":"Barst","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"2026032101021998600_bib4","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Galie","year":"2005","journal-title":"N Engl J Med"},{"key":"2026032101021998600_bib5","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Galie","year":"2009","journal-title":"Circulation"},{"key":"2026032101021998600_bib6","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"2026032101021998600_bib7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","article-title":"Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial","volume":"149","author":"Simonneau","year":"2008","journal-title":"Ann Intern Med"},{"key":"2026032101021998600_bib8","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101021998600_bib9","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Galie","year":"2008","journal-title":"Circulation"},{"key":"2026032101021998600_bib10","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.ahj.2007.02.037","article-title":"A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology","volume":"153","author":"Macchia","year":"2007","journal-title":"Am Heart J"},{"key":"2026032101021998600_bib11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2174\/157488711796575504","article-title":"Clinical trials using vasodilators in pulmonary arterial hypertension: where do we go from here?","volume":"6","author":"Macchia","year":"2011","journal-title":"Rev Recent Clin Trials"},{"key":"2026032101021998600_bib12","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/j.jacc.2009.04.007","article-title":"End points and clinical trial design in pulmonary arterial hypertension","volume":"54","author":"McLaughlin","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026032101021998600_bib13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00002281-200203000-00006","article-title":"Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research","volume":"14","author":"Beaton","year":"2002","journal-title":"Curr Opin Rheumatol"},{"key":"2026032101021998600_bib14","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1183\/09031936.00063810","article-title":"The minimal important difference of exercise tests in severe COPD","volume":"37","author":"Puhan","year":"2011","journal-title":"Eur Respir J"},{"key":"2026032101021998600_bib15","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1164\/ajrccm.155.4.9105067","article-title":"Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients","volume":"155","author":"Redelmeier","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101021998600_bib16","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/hrt.80.4.377","article-title":"Reproducibility and responsiveness of quality of life assessment and six minute walk test in elderly heart failure patients","volume":"80","author":"O\u2019Keeffe","year":"1998","journal-title":"Heart"},{"key":"2026032101021998600_bib17","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1164\/rccm.201007-1179OC","article-title":"Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference","volume":"183","author":"du Bois","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101021998600_bib18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1378\/chest.07-0275","article-title":"Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil","volume":"135","author":"Gilbert","year":"2009","journal-title":"Chest"},{"key":"2026032101021998600_bib19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","article-title":"Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes","volume":"61","author":"Revicki","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"2026032101021998600_bib20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jclinepi.2009.01.024","article-title":"The minimal detectable change cannot reliably replace the minimal important difference","volume":"63","author":"Turner","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"2026032101021998600_bib21","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1046\/j.1525-1497.2002.11111.x","article-title":"Determination of the clinical importance of study results","volume":"17","author":"Man-Son-Hing","year":"2002","journal-title":"J Gen Intern Med"},{"key":"2026032101021998600_bib22","author":"Ware"},{"key":"2026032101021998600_bib23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101021998600_bib24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/00005650-199401000-00004","article-title":"The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups","volume":"32","author":"McHorney","year":"1994","journal-title":"Med Care"},{"key":"2026032101021998600_bib25","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1185\/03007990903210066","article-title":"Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension","volume":"25","author":"Pepke-Zaba","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"2026032101021998600_bib26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1378\/chest.07-0592","article-title":"Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension","volume":"133","author":"Pepke-Zaba","year":"2008","journal-title":"Chest"},{"key":"2026032101021998600_bib27","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.rmed.2006.04.023","article-title":"Relative responsiveness of the Chronic Respiratory Questionnaire, St. Georges Respiratory Questionnaire and four other health-related quality of life instruments for patients with chronic lung disease","volume":"101","author":"Puhan","year":"2007","journal-title":"Respir Med"},{"key":"2026032101021998600_bib28","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4065\/77.4.371","article-title":"Methods to explain the clinical significance of health status measures","volume":"77","author":"Guyatt","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"2026032101021998600_bib29","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1097\/00005650-198903001-00015","article-title":"Effect sizes for interpreting changes in health status","volume":"27","author":"Kazis","year":"1989","journal-title":"Med Care"},{"key":"2026032101021998600_bib30","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s11136-004-0027-4","article-title":"Quantifying responsiveness of quality of life measures without an external criterion","volume":"14","author":"Zou","year":"2005","journal-title":"Qual Life Res"},{"key":"2026032101021998600_bib31","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0895-4356(99)00071-2","article-title":"Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life","volume":"52","author":"Wyrwich","year":"1999","journal-title":"J Clin Epidemiol"},{"key":"2026032101021998600_bib32","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","article-title":"Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation","volume":"41","author":"Norman","year":"2003","journal-title":"Med Care"},{"key":"2026032101021998600_bib33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1081\/COPD-200050508","article-title":"Bridging the gap: using triangulation methodology to estimate minimal clinically important differences (MCIDs)","volume":"2","author":"Leidy","year":"2005","journal-title":"COPD"},{"key":"2026032101021998600_bib34","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1183\/09031936.00140507","article-title":"Interpretation of treatment changes in 6-minute walk distance in patients with COPD","volume":"32","author":"Puhan","year":"2008","journal-title":"Eur Respir J"},{"key":"2026032101021998600_bib35","first-page":"1197","article-title":"How well is the clinical importance of study results reported? An assessment of randomized controlled trials","volume":"165","author":"Chan","year":"2001","journal-title":"CMAJ"},{"key":"2026032101021998600_bib36","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1378\/chest.10-1066","article-title":"Clinically significant change in stroke volume in pulmonary hypertension","volume":"139","author":"van Wolferen","year":"2011","journal-title":"Chest"},{"key":"2026032101021998600_bib37","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1183\/09031936.04.00028404","article-title":"Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2","volume":"24","author":"Humbert","year":"2004","journal-title":"Eur Respir J"},{"key":"2026032101021998600_bib38","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.apmr.2009.10.017","article-title":"Updating the minimal important difference for six-minute walk distance in patients with chronic obstructive pulmonary disease","volume":"91","author":"Holland","year":"2010","journal-title":"Arch Phys Med Rehabil"},{"key":"2026032101021998600_bib39","first-page":"A4829","article-title":"The impact of health-related quality of life on outcomes in pulmonary arterial hypertension [abstract]","volume":"181","author":"Mathai","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101021998600_bib40"},{"key":"2026032101021998600_bib41","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/j.jacc.2011.06.068","article-title":"Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy","volume":"58","author":"van de Veerdonk","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026032101021998600_bib42","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.rmed.2009.04.024","article-title":"Small changes in six-minute walk distance are important in diffuse parenchymal lung disease","volume":"103","author":"Holland","year":"2009","journal-title":"Respir Med"},{"key":"2026032101021998600_bib43","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1532-5415.2006.00701.x","article-title":"Meaningful change and responsiveness in common physical performance measures in older adults","volume":"54","author":"Perera","year":"2006","journal-title":"J Am Geriatr Soc"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/186\/5\/428\/67292114\/ajrccm_186_5_428.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/186\/5\/428\/67292114\/ajrccm_186_5_428.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T05:02:28Z","timestamp":1774069348000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/186\/5\/428\/8507737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,1]]},"references-count":43,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2012,9,1]]},"published-print":{"date-parts":[[2012,9,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201203-0480oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,9]]},"published":{"date-parts":[[2012,9,1]]}}}